0
0
0
0
1
2
3
$0
Is Eli Lilly solid or fragile? The Finex Financial Health Scanner reads LLY's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $65.2B |
|---|---|
| Net income | $20.6B |
| Operating margin | 40.4% |
| Net margin | 31.7% |
| Cash and investments | $7.3B |
| Total debt | $42.5B |
| Free cash flow | $9.3B |
| Revenue growth (1 year) | 44.7% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.